• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用含磺胺类抗疟药和青蒿素类药物的药物导致的药物不良反应:坦桑尼亚农村三个具有常规人口监测系统的地区的发病率和家庭成本调查结果。

Adverse drug events resulting from use of drugs with sulphonamide-containing anti-malarials and artemisinin-based ingredients: findings on incidence and household costs from three districts with routine demographic surveillance systems in rural Tanzania.

机构信息

Department of Health Policy and Management, Rollins School of Public Health (Emory University), Atlanta, GA 30322, USA.

出版信息

Malar J. 2013 Jul 11;12:236. doi: 10.1186/1475-2875-12-236.

DOI:10.1186/1475-2875-12-236
PMID:23844934
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3710484/
Abstract

BACKGROUND

Anti-malarial regimens containing sulphonamide or artemisinin ingredients are widely used in malaria-endemic countries. However, evidence of the incidence of adverse drug reactions (ADR) to these drugs is limited, especially in Africa, and there is a complete absence of information on the economic burden such ADR place on patients. This study aimed to document ADR incidence and associated household costs in three high malaria transmission districts in rural Tanzania covered by demographic surveillance systems.

METHODS

Active and passive surveillance methods were used to identify ADR from sulphadoxine-pyrimethamine (SP) and artemisinin (AS) use. ADR were identified by trained clinicians at health facilities (passive surveillance) and through cross-sectional household surveys (active surveillance). Potential cases were followed up at home, where a complete history and physical examination was undertaken, and household cost data collected. Patients were classified as having 'possible' or 'probable' ADR by a physician.

RESULTS

A total of 95 suspected ADR were identified during a two-year period, of which 79 were traced, and 67 reported use of SP and/or AS prior to ADR onset. Thirty-four cases were classified as 'probable' and 33 as 'possible' ADRs. Most (53) cases were associated with SP monotherapy, 13 with the AS/SP combination (available in one of the two areas only), and one with AS monotherapy. Annual ADR incidence per 100,000 exposures was estimated based on 'probable' ADR only at 5.6 for AS/SP in combination, and 25.0 and 11.6 for SP monotherapy. Median ADR treatment costs per episode ranged from US$2.23 for those making a single provider visit to US$146.93 for patients with four visits. Seventy-three per cent of patients used out-of-pocket funds or sold part of their farm harvests to pay for treatment, and 19% borrowed money.

CONCLUSION

Both passive and active surveillance methods proved feasible methods for anti-malarial ADR surveillance, with active surveillance being an important complement to facility-based surveillance, given the widespread practice of self-medication. Household costs associated with ADR treatment were high and potentially catastrophic. Efforts should be made to both improve pharmacovigilance across Africa and to identify strategies to reduce the economic burden endured by households suffering from ADR.

摘要

背景

含有磺胺或青蒿素成分的抗疟方案在疟疾流行国家广泛使用。然而,这些药物不良反应(ADR)发生率的证据有限,特别是在非洲,而且对于这些 ADR 给患者带来的经济负担,完全没有信息。本研究旨在记录在坦桑尼亚农村三个疟疾高传播地区,使用磺胺多辛-乙胺嘧啶(SP)和青蒿素(AS)的 ADR 发生率,并评估其相关家庭成本。

方法

采用主动和被动监测方法,从磺胺多辛-乙胺嘧啶(SP)和青蒿素(AS)的使用中识别 ADR。通过训练有素的临床医生在医疗机构(被动监测)和通过横断面家庭调查(主动监测)来识别 ADR。对疑似病例进行家庭随访,进行完整的病史和体格检查,并收集家庭费用数据。医生将疑似病例分为“可能”和“确定”的 ADR。

结果

在两年期间共发现 95 例疑似 ADR,其中 79 例得到追踪,67 例在 ADR 发生前报告使用 SP 和/或 AS。34 例被分类为“确定”和 33 例为“可能”ADR。大多数(53 例)与 SP 单药治疗有关,13 例与 AS/SP 联合治疗有关(仅在两个地区中的一个地区可用),1 例与 AS 单药治疗有关。基于“确定”的 ADR,每年每 10 万例暴露的 ADR 发生率估计为 AS/SP 联合用药为 5.6,SP 单药治疗为 25.0 和 11.6。每次 ADR 治疗的中位费用从单次就诊的 2.23 美元到 4 次就诊的 146.93 美元不等。73%的患者使用自费资金或出售部分农作物来支付治疗费用,19%的患者借钱。

结论

被动和主动监测方法均被证明是抗疟 ADR 监测的可行方法,主动监测是对医疗机构监测的重要补充,因为自我用药的情况普遍存在。ADR 治疗相关的家庭成本很高,可能会造成灾难性后果。应努力在整个非洲改善药物警戒,并确定减轻遭受 ADR 之苦的家庭经济负担的策略。

相似文献

1
Adverse drug events resulting from use of drugs with sulphonamide-containing anti-malarials and artemisinin-based ingredients: findings on incidence and household costs from three districts with routine demographic surveillance systems in rural Tanzania.使用含磺胺类抗疟药和青蒿素类药物的药物导致的药物不良反应:坦桑尼亚农村三个具有常规人口监测系统的地区的发病率和家庭成本调查结果。
Malar J. 2013 Jul 11;12:236. doi: 10.1186/1475-2875-12-236.
2
Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso.加强撒哈拉以南非洲地区药物警戒的最佳方法和策略:布基纳法索纳诺罗健康与人口监测系统中接受一线青蒿素联合疗法治疗患者的队列研究
Drug Des Devel Ther. 2020 Apr 16;14:1507-1521. doi: 10.2147/DDDT.S224857. eCollection 2020.
3
Routine delivery of artemisinin-based combination treatment at fixed health facilities reduces malaria prevalence in Tanzania: an observational study.在固定卫生机构常规提供青蒿素复方疗法可降低坦桑尼亚的疟疾发病率:一项观察性研究。
Malar J. 2012 Apr 30;11:140. doi: 10.1186/1475-2875-11-140.
4
Malaria pharmacovigilance in Africa: lessons from a pilot project in Mpumalanga Province, South Africa.非洲疟疾药物警戒:南非姆普马兰加省一个试点项目的经验教训
Drug Saf. 2007;30(10):899-910. doi: 10.2165/00002018-200730100-00008.
5
Anti-malarial drug safety information obtained through routine monitoring in a rural district of South-Western Senegal.通过在塞内加尔西南部农村地区的常规监测获得的抗疟药物安全性信息。
Malar J. 2012 Dec 5;11:402. doi: 10.1186/1475-2875-11-402.
6
Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring.抗疟药物(包括青蒿素类复方疗法)不良反应全球报告情况评估,向世界卫生组织国际药物监测规划报告。
Malar J. 2011 Mar 9;10:57. doi: 10.1186/1475-2875-10-57.
7
Access to artemisinin-based anti-malarial treatment and its related factors in rural Tanzania.坦桑尼亚农村获得青蒿素类抗疟治疗及其相关因素。
Malar J. 2013 May 7;12:155. doi: 10.1186/1475-2875-12-155.
8
Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania.基于青蒿素的抗疟药治疗非重症疟疾的疗效和安全性监测:坦桑尼亚抗疟治疗疗效试验实施证据综述
Malar J. 2015 Mar 29;14:135. doi: 10.1186/s12936-015-0649-8.
9
Experience of safety monitoring in the context of a prospective observational study of artemether-lumefantrine in rural Tanzania: lessons learned for pharmacovigilance reporting.在坦桑尼亚农村地区开展的青蒿琥酯-咯萘啶前瞻性观察研究中进行安全性监测的经验:药物警戒报告的经验教训。
Malar J. 2010 Jul 14;9:205. doi: 10.1186/1475-2875-9-205.
10
The Burden of Adverse Drug Reactions Due to Artemisinin-Based Antimalarial Treatment in Selected Ugandan Health Facilities: An Active Follow-Up Study.在选定的乌干达医疗机构中,基于青蒿素的抗疟治疗导致的药物不良反应负担:一项主动随访研究。
Drug Saf. 2018 Aug;41(8):753-765. doi: 10.1007/s40264-018-0659-x.

引用本文的文献

1
Variation of adverse drug events in different settings in Africa: a systematic review.非洲不同环境下药物不良反应的变化:系统评价。
Eur J Med Res. 2024 Jun 16;29(1):333. doi: 10.1186/s40001-024-01934-0.
2
Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso.加强撒哈拉以南非洲地区药物警戒的最佳方法和策略:布基纳法索纳诺罗健康与人口监测系统中接受一线青蒿素联合疗法治疗患者的队列研究
Drug Des Devel Ther. 2020 Apr 16;14:1507-1521. doi: 10.2147/DDDT.S224857. eCollection 2020.
3
Risk factors for placental malaria and associated adverse pregnancy outcomes in Rufiji, Tanzania: a hospital based cross sectional study.坦桑尼亚鲁菲吉地区胎盘疟疾及相关不良妊娠结局的危险因素:一项基于医院的横断面研究
Afr Health Sci. 2015 Sep;15(3):810-8. doi: 10.4314/ahs.v15i3.15.
4
Placental malaria is rare among Zanzibari pregnant women who did not receive intermittent preventive treatment in pregnancy.在未接受孕期间歇性预防治疗的桑给巴尔孕妇中,胎盘疟疾较为罕见。
Am J Trop Med Hyg. 2014 Aug;91(2):367-373. doi: 10.4269/ajtmh.13-0586. Epub 2014 Jun 2.

本文引用的文献

1
Routine delivery of artemisinin-based combination treatment at fixed health facilities reduces malaria prevalence in Tanzania: an observational study.在固定卫生机构常规提供青蒿素复方疗法可降低坦桑尼亚的疟疾发病率:一项观察性研究。
Malar J. 2012 Apr 30;11:140. doi: 10.1186/1475-2875-11-140.
2
Poor quality vital anti-malarials in Africa - an urgent neglected public health priority.非洲劣质基本抗疟药物——亟待关注的公共卫生疏忽领域
Malar J. 2011 Dec 13;10:352. doi: 10.1186/1475-2875-10-352.
3
Malaria and HIV co-infection in pregnancy in sub-Saharan Africa: impact of treatment using antimalarial and antiretroviral agents.撒哈拉以南非洲妊娠合并疟疾和艾滋病毒感染:抗疟和抗逆转录病毒药物治疗的影响。
Trans R Soc Trop Med Hyg. 2009 Aug;103(8):761-7. doi: 10.1016/j.trstmh.2008.06.017. Epub 2008 Aug 15.
4
Surveillance for adverse drug reactions to combination antimalarial therapy with sulfadoxine-pyrimethamine plus artesunate in Peru.秘鲁对磺胺多辛-乙胺嘧啶联合青蒿琥酯抗疟联合疗法的药物不良反应监测。
Am J Trop Med Hyg. 2008 Jul;79(1):42-4.
5
Antimalarial drug quality in the most severely malarious parts of Africa - a six country study.非洲疟疾最严重地区的抗疟药物质量——一项六国研究
PLoS One. 2008 May 7;3(5):e2132. doi: 10.1371/journal.pone.0002132.
6
Household burden of malaria in South Africa and Mozambique: is there a catastrophic impact?南非和莫桑比克疟疾的家庭负担:是否存在灾难性影响?
Trop Med Int Health. 2008 Jan;13(1):108-22. doi: 10.1111/j.1365-3156.2007.01979.x.
7
The costs of introducing artemisinin-based combination therapy: evidence from district-wide implementation in rural Tanzania.采用青蒿素联合疗法的成本:来自坦桑尼亚农村地区全面实施的证据。
Malar J. 2008 Jan 7;7:4. doi: 10.1186/1475-2875-7-4.
8
A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies.疟疾治疗的一项重大转变:以青蒿素为基础的联合疗法的采用与推广。
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):193-7.
9
Malaria pharmacovigilance in Africa: lessons from a pilot project in Mpumalanga Province, South Africa.非洲疟疾药物警戒:南非姆普马兰加省一个试点项目的经验教训
Drug Saf. 2007;30(10):899-910. doi: 10.2165/00002018-200730100-00008.
10
Pharmacovigilance in developing countries.发展中国家的药物警戒
BMJ. 2007 Sep 8;335(7618):462. doi: 10.1136/bmj.39323.586123.BE.